Ginseng, cistanche and polygonatum sibiricum composition capable of improving erectile dysfunction caused by aging and preparation method of ginseng, cistanche and polygonatum sibiricum composition

Abstract

The invention discloses a ginseng, herba cistanche and rhizoma polygonati composition capable of improving erectile dysfunction caused by aging and a preparation method, and belongs to the field of food processing. The preparation method comprises the following steps: (1) taking processed product raw materials, adjusting the moisture content of the processed product raw materials to 60-80%, and then sealing the processed product raw materials; (2) carrying out heat preservation on the sealed raw materials; (3) taking out the raw materials subjected to heat preservation, and drying until the moisture content of the raw materials is reduced to 15-40%; (4) sealing the raw materials treated in the step (3), and carrying out heat preservation; and (5) taking out the raw materials treated in the step (4), and drying to obtain the processed product. The contents of glucose and maltose in the raw materials are improved by pretreating the raw materials of ginseng, cistanche and rhizoma polygonati, and the functional food ingredient in which the sum of the content of AFG and the content of FuArg is 2.5%-8% and the mass ratio of AFG to FuArg is 5: 1-1: 3 is finally prepared through the processes of moisture regulation, sealing, heat preservation and the like. The traditional Chinese medicine composition has an obvious effect of improving erectile dysfunction caused by aging.

Description

Technical Field

[0001] The present invention relates to the field of food processing, and particularly to a composition of ginseng, cistanche deserticola, and polygonatum sibiricum for improving erectile dysfunction caused by aging and a preparation method thereof. Background Art

[0002] Ginseng and polygonatum sibiricum planted for five years or less are both raw materials that can be used as both medicine and food. Their traditional processing methods are one or more times of steaming and sun-drying treatments (polygonatum sibiricum is traditionally processed by nine times of steaming and nine times of sun-drying). The processed products obtained are called red ginseng, fairy's surplus food, etc., and are considered to have functions such as anti-aging and promoting male reproductive health. The raw material that can be used as both medicine and food, cistanche deserticola, is considered to have effects such as improving male health and softening blood vessels.

[0003] Traditionally, the beneficial health effects of red ginseng are considered to be due to the presence of low-polarity saponins such as Rg2, Rh1, Rg3, and ginseng polysaccharides; the effects of fairy's surplus food are usually attributed to its polygonatum polysaccharides, flavonoid components, and steroidal saponin compounds; the effect of cistanche deserticola in improving male health is considered to be due to its middle phenylpropanoid glycosides, iridoid glycosides, and lignan components. However, in contrast to these traditional understandings, during the processing of raw materials that can be used as both medicine and food (such as ginseng planted for five years or less processed into red ginseng, polygonatum sibiricum processed into fairy's surplus food, and the traditional drying of cistanche deserticola), there is often a certain degree of polysaccharide degradation, partial conversion of saponins into sapogenins, and loss of heat-sensitive flavonoid components. If these components are indeed playing a role, the efficacy of the processed raw materials will be weakened due to the reduction in the content of these efficacy components! Therefore, we have reason to believe that during the processing of these raw materials that can be used as both medicine and food, it is very likely that reactions occur between the components that originally exist in the raw materials and have general functional activities, forming new components with strong physiological activities.

[0004] For the above reasons, it is of great significance to systematically analyze the traditional processing technology / experience of raw materials that can be used as both medicine and food, confirm the newly formed components in the processed raw materials and their action mechanisms, and improve the content of these new components and strengthen their beneficial health effects through precise control of the processing process, so as to improve the scientific nature of the processing technology of raw materials that can be used as both medicine and food, standardize the production process, and achieve controllable product quality, and safeguard the health rights and interests of consumers. Summary of the Invention

[0005] Technical Problem

[0006] At present, the processing process of traditional raw materials that can be used as both medicine and food lacks systematic analysis, and there is a lack of in-depth research on the component changes of raw materials during the processing process and the functions of the processed products. Therefore, it is necessary to explore the processing process of traditional raw materials that can be used as both medicine and food, such as ginseng, cistanche deserticola, polygonatum sibiricum, etc., to understand the component changes of the raw materials and optimize their processing technology.

[0007] Technical Content

[0008] The research of the present invention has found that for ginseng, cistanche, and polygonatum planted for five years or less, the content of glucose and maltose in them can be increased through raw material pretreatment. Arginine is the dominant amino acid in the three raw materials after pretreatment, and its content accounts for more than 50% of the total free amino acids. In the traditional processing technology, it usually undergoes a thermal processing stage with a certain period of low system moisture (5% - 25%) and relatively high temperature (95°C - 110°C). Such environmental conditions are conducive to the Maillard initial reaction between free amino acids and reducing sugars, forming Amadori Compounds (ACs) with good stability and possibly having physiological activity. In this treatment stage, arginine in ginseng, polygonatum, and cistanche planted for five years or less will react with maltose and glucose to form Arginyl-Fructosyl-Glucose (AFG) and FruArg. Especially when the mass ratio of AFG and FruArg in the product system is within the range of 5:1 - 1:3 and the sum of the two accounts for 2.5% - 8% of the product quality, the product has a significant effect on improving erectile dysfunction caused by aging.

[0009] The first object of the present invention is to provide a composition for relieving male sexual dysfunction caused by aging, and the composition is composed of Arginyl-Fructosyl-Glucose (AFG) and FruArg.

[0010] Furthermore, the mass ratio of Arginyl-Fructosyl-Glucose to FruArg in the composition is 8:1 - 1:3.

[0011] Furthermore, the mass ratio of Arginyl-Fructosyl-Glucose to FruArg in the composition is 6:1 - 1:3.

[0012] Preferably, the mass ratio of Arginyl-Fructosyl-Glucose to FruArg in the composition is 5:1 - 1:3.

[0013] Furthermore, Arginyl-Fructosyl-Glucose can be prepared according to the following method: Add maltose and arginine to water, adjust the pH of the solution to neutral, and then start heating and reacting, and then purify and separate to obtain Arginyl-Fructosyl-Glucose.

[0014] Furthermore, the molar ratio of maltose to arginine is 0.5 - 1.5:1.

[0015] Furthermore, the pH of the solution is 6.5 - 7.5.

[0016] Furthermore, the heating reaction is to heat and react at 80 - 90°C for 0.5 - 2 hours.

[0017] Further, the purification can be column purification or gas chromatography purification; when column purification is selected, the resin can be Dowex50WX4 ion exchange resin.

[0018] Further, the fructosyl arginine can be prepared by the following method: adding glucose and arginine into water, adjusting the pH of the solution to neutral and then starting the heating reaction, and then purifying and separating to obtain fructosyl arginine.

[0019] Further, the molar ratio of glucose to arginine is 0.5 - 1.5:1.

[0020] Further, the pH of the solution is 6.5 - 7.5.

[0021] Further, the heating reaction is carried out at 80 - 90 °C for 0.5 - 2 hours.

[0022] Further, the purification can be column purification or gas chromatography purification; when column purification is selected, the resin can be Dowex50WX4 ion exchange resin.

[0023] The second object of the present invention is to provide the application of the above composition for relieving male sexual dysfunction caused by aging in the preparation of drugs.

[0024] The third object of the present invention is to provide a processed product for relieving male sexual dysfunction caused by aging, and the mass ratio of AFG and FruArg in the processed product is 8:1 - 1:3.

[0025] Further, the mass ratio of arginyl fructosyl glucose and fructosyl arginine in the processed product is 6:1 - 1:3.

[0026] Preferably, the mass ratio of arginyl fructosyl glucose and fructosyl arginine in the processed product is 5:1 - 1:3.

[0027] Further, the processed product includes one or more of red ginseng, cistanche deserticola, and polygonatum sibiricum.

[0028] The fourth object of the present invention is to provide a preparation method of a processed product with high AFG and FruArg content and having the function of relieving male sexual dysfunction caused by aging, and the preparation method includes the following steps:

[0029] (1) Take the raw materials of the processed product, adjust its moisture content to 60% - 80% and then seal it;

[0030] (2) Keep the sealed raw materials of the processed product warm;

[0031] (3) Take out the warmed raw materials of the processed product and dry them until their moisture content is reduced to 15 - 40%;

[0032] (4) Seal and keep warm the processed crude drug materials obtained in step (3).

[0033] (5) Take out the processed crude drug materials obtained in step (4) and dry them until their moisture content is lower than 10%, thus obtaining the processed drugs.

[0034] Further, the crude drug materials in step (1) are one or more of ginseng, cistanche, and polygonatum sibiricum.

[0035] Further, the ginseng, cistanche, and polygonatum sibiricum are those planted for five years or less.

[0036] Further, the crude drug materials can be whole raw materials, raw materials cut into pieces, raw materials pulverized, or raw materials made into pulp.

[0037] Further, when the crude drug materials are a mixture of ginseng and polygonatum sibiricum, the mass ratio of ginseng to polygonatum sibiricum is 0.5 - 1.5:1.

[0038] Further, when the crude drug materials are a mixture of ginseng and cistanche, the mass ratio of ginseng to cistanche is 1.5 - 2.5:1.

[0039] Further, when the crude drug materials are a mixture of polygonatum sibiricum and cistanche, the mass ratio of polygonatum sibiricum to cistanche is 0.5 - 1.5:2.

[0040] Further, when the crude drug materials are a mixture of ginseng, polygonatum sibiricum, and cistanche, the mass ratio of ginseng, polygonatum sibiricum, and cistanche is 0.5 - 1.5:0.5 - 1.5:1.

[0041] Further, the process of adjusting the moisture content in step (1) is specifically: placing the crude drug materials at 50 - 60°C to remove moisture.

[0042] Further, the moisture content in step (1) is adjusted to 65% - 80%.

[0043] Further, the sealing and heat preservation in step (2) is to keep warm at 50 - 60°C for 48 - 72 hours.

[0044] Further, the drying in step (3) includes high-temperature drying, natural air drying, or vacuum drying.

[0045] Further, the temperature of the high-temperature drying is 90 - 105°C.

[0046] Further, the moisture content in step (3) is reduced to 15 - 30%.

[0047] Further, the processed crude drug materials in step (4) can be any one of ginseng, cistanche deserticola, and polygonatum sibiricum processed through step (3), or any two or three combinations of ginseng, cistanche deserticola, and polygonatum sibiricum respectively processed through steps (1) to (3), or the processed crude drug materials obtained by jointly processing any two or three combinations of ginseng, cistanche deserticola, and polygonatum sibiricum through steps (1) to (3).

[0048] Further, the sealed heat preservation in step (4) is carried out at a temperature of 90°C to 110°C for 30 to 150 minutes.

[0049] Further, the drying in step (5) includes high-temperature drying, natural air drying, or vacuum drying.

[0050] Further, the temperature of the high-temperature drying is 90 to 105°C.

[0051] Further, the moisture content after drying in step (5) is 8 to 10%.

[0052] Advantages of the present invention:

[0053] The present invention improves the contents of glucose and maltose in the raw materials by pre-treating the raw materials of ginseng, cistanche deserticola, and polygonatum sibiricum, and adjusts the composition and ratio thereof according to the contents of glucose, maltose, and arginine in the three raw materials to obtain a combined material with the dry basis contents of glucose and maltose both not less than 2%, the dry basis content of the sum of the two reaching more than 5%, the arginine content not less than 1.5% (dry basis), and the proportion of arginine in the total free amino acids not less than 50%. The combined material can be processed through processes such as moisture control and sealed heat preservation to obtain a functional food ingredient with the sum of the contents of AFG and FruArg being 2.5% to 8%, and the mass ratio of AFG to FruArg being 5:1 to 1:3. The functional food ingredient has been verified by experiments to have an obvious effect of improving erectile dysfunction caused by aging. Description of the drawings

[0054] Figure 1 Are the chemical structural formulas of Arginyl-Fructosyl-Glucose (AFG) and FruArg.

[0055] Figure 2 Are the mass spectra (ESI+ mode) of self-synthesized AFG and FruArg standard products.

[0056] Figure 3 Are the chromatograms of self-synthesized AFG and FruArg standard products detected by high performance liquid chromatography-tandem evaporative light scattering detector.

[0057] Figure 4 Are the contents of glucose and maltose in the raw materials before and after pre-treatment in Example 2.

[0058] Figure 5 The total ion chromatograms of AFG and FruArg in the processed samples obtained in Example 2 by UPLC-MS / MS. Detailed implementation manners

[0059] To make the above objects, features and advantages of the present invention more obvious and understandable, the following detailed description of the specific implementation manners of the present invention will be given in conjunction with the embodiments of the specification.

[0060] In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention may be implemented in other ways different from those described herein. Those skilled in the art can make similar extensions without departing from the connotation of the present invention. Therefore, the present invention is not limited by the specific embodiments disclosed below.

[0061] Secondly, the so-called "one embodiment" or "embodiment" herein refers to a specific feature, structure or characteristic that may be included in at least one implementation manner of the present invention. The appearances of "in one embodiment" in different places in this specification do not all refer to the same embodiment, nor are they separate or alternative embodiments that exclude each other with other embodiments.

[0062] Source of raw materials

[0063] D-galactose was purchased from Beijing Solarbio Science & Technology Co., Ltd.; tadalafil was purchased from Menarini (China) Co., Ltd.; ginseng was purchased from Fusong County, Jilin Province; polygonatum was purchased from Nanchang City, Jiangxi Province.

[0064] Both AFG and FruArg were self-made. The specific process for preparing AFG was as follows: Maltose and arginine were dissolved in water at a molar ratio of 1:1, the pH of the solution was adjusted to 7.4, and then the reaction was heated at 90 °C for 1 h using a rotary evaporator. Subsequently, AFG was separated from the reaction mixture using Dowex 50WX4 ion exchange resin (hydrogen form), and the purity of the obtained AFG was detected to be 99.61% by high performance liquid chromatography tandem evaporative light scattering detector; the specific process for preparing FruArg was as follows: Glucose and arginine were dissolved in water at a molar ratio of 1:1, the pH of the solution was adjusted to 7.4, and then the reaction was heated at 90 °C for 1 h using a rotary evaporator. Subsequently, FruArg was separated from the reaction mixture using Dowex 50WX4 ion exchange resin (hydrogen form), and the purity of the obtained FruArg was detected to be 98.83% by high performance liquid chromatography tandem evaporative light scattering detector.

[0065] Detection process

[0066] Detection of the contents of AFG, FruArg, 5-HMF, and AA in each processed herbal medicine in the following examples: Qualitative and quantitative analysis was performed using an optimized ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS / MS) method within a 10-minute running time. The specific process is as follows:

[0067] 1. Synchronous qualitative and quantitative analysis method for AFG and FruArg

[0068] 1.1 Instruments: Ultra-high performance liquid chromatography tandem quadrupole mass spectrometer (UPLC-TQD, Waters, USA); Chromatographic column: ACQUITY UPLC BEH C18 (100×2.1 mm, 1.7 μm);

[0069] 1.2 Liquid chromatography conditions: The mobile phase was 100% acetonitrile (phase A) and 0.1% formic acid in water (v / v) (phase B). Column temperature: 35°C, flow rate: 0.3 mL / min, injection volume: 3 μL. The gradient elution program was as follows: 0 - 5 min, the volume fraction of phase B changed from 100% to 90%; 5 - 6 min, the volume fraction of phase B changed from 90% to 50%; 6 - 7 min, the volume fraction of phase B changed from 50% to 20%; 7 - 9 min, the volume fraction of phase B was maintained at 20%; 9 - 10 min, the volume fraction of phase B returned from 20% to the initial 100% B; The total running time was 10 min.

[0070] 1.3 Mass spectrometry detection conditions: Equipped with an electrospray ionization source and the positive ion mode (ESI+) was selected. Ion source temperature: 120°C; Desolvation gas temperature: 400°C; Capillary voltage: 3.0 kV; Detection voltage: 1800 V; High-purity nitrogen (N 2 ): Purity greater than 99.99%. Cone gas (N 2 ) flow rate: 50 L / h; Desolvation gas (N 2 ) flow rate: 800 L / h; Mass spectrometry scan range: 50 - 1000 m / z. Multiple reaction monitoring (MRM) mode was used for precise quantitative analysis. The optimized parameters such as cone voltage, collision energy, and quantitative product ions are shown in Table 1.

[0071] Table 1 Mass spectrometry parameters of AFG and FruArg

[0072] Analyte Cone voltage (eV) Collision energy (eV) Parent ion (m / z) Quantification ion (m / z) AFG 40 5 499.68 499.68 FruArg 30 20 337.10 114.03

[0073] 2. UPLC-MS / MS qualitative and quantitative analysis method for 5-hydroxymethylfurfural (5-HMF) and acrylamide (AA)

[0074] 2.1 Instruments: Ultra Performance Liquid Chromatography-Tandem Quadrupole Mass Spectrometer (UPLC-TQD, Waters, USA); Chromatographic column: ACQUITY UPLC BEH C18 (100×2.1 mm, 1.7 μm);

[0075] 2.2 Liquid Chromatography conditions: The mobile phase was 100% acetonitrile (Phase A) and 0.1% formic acid in water (v / v) (Phase B). Column temperature: 35 °C, flow rate: 0.3 mL / min, injection volume: 3 μL. The gradient elution program was as follows: 0 - 5 min, the volume fraction of Phase B changed from 100% to 50%; 5 - 10 min, the volume fraction of Phase B changed from 50% to 0%; 10 - 12 min, the volume fraction of Phase B changed from 0% to 100%; 12 - 15 min, the volume fraction of Phase B was maintained at 100%; The total running time was 15 min.

[0076] 2.3 Mass spectrometry detection conditions were the same as those in 1.3 above. The MRM mode was used for precise quantitative analysis. The optimized parameters such as cone voltage, collision energy, and quantitative product ions are shown in Table 2.

[0077] Table 2 Optimized mass spectrometry parameters for 5-HMF and AA

[0078] Analyte Cone voltage (eV) Collision energy (eV) Parent ion (m / z) Quantification ion (m / z) 5-HMF 30 13 126.60 109.00 AA 26 13 72.1 55.49

[0079] Example 1 Evaluation of the effect of the composition of AFG and FruArg on improving senile erectile dysfunction

[0080] Experimental animals: 64 healthy male SPF-grade SD rats at 8 weeks old.

[0081] Experimental grouping: Group C: Blank control group; gavaged with 0.5% CMC-Na normal saline; Group D: D-galactose (D-gal) model control group; gavaged with 0.5% CMC-Na normal saline; Group P: Tadalafil positive control group, gavaged with 0.52 mg / kg BW;

[0082] Sample-1 group: The gavaged sample was a composition prepared according to the mass ratio of AFG:FruArg = 5:1. The gavaged sample was calculated based on the sum of AFG and FruArg at 40 mg / kg BW;

[0083] Sample-2 group: The gavaged sample was a composition prepared according to the mass ratio of AFG:FruArg = 1:3. The gavaged sample was calculated based on the sum of AFG and FruArg at 40 mg / kg BW;

[0084] Sample-3 group: The gavaged sample was a composition prepared according to the mass ratio of AFG:FruArg = 2:1. The gavaged sample was calculated based on the sum of AFG and FruArg at 40 mg / kg BW;

[0085] Sample - Group 4: The gavage sample was a composition prepared at a mass ratio of AFG:FruArg = 10:1, and the gavage sample was 40 mg / kg BW in terms of the sum of AFG and FruArg;

[0086] Sample - Group 5: The gavage sample was a composition prepared at a mass ratio of AFG:FruArg = 1:5, and the gavage sample was 40 mg / kg BW in terms of the sum of AFG and FruArg;

[0087] Except for Group C, the remaining groups were intraperitoneally injected with D - gal at a dose of 150 mg / kg BW every day for 9 consecutive weeks. Starting from the 6th week, intraperitoneal injection and gavage were carried out simultaneously for 4 consecutive weeks.

[0088] Test results:

[0089] 1) Effects of the composition of AFG and FruArg on the body weight and penis weight in senescence

[0090] Table 3 Average body weight and penis mass of rats in each group during the test

[0091]

[0092]

[0093] Note: a indicates that for the same index, there is no significant difference between different groups (P > 0.05).

[0094] As shown in Table 3, there was no significant difference in the body weight and penis weight of rats in each group (P > 0.05), indicating that the composition of AFG and FruArg had no significant regulatory effect on the body weight and penis weight of rats.

[0095] 2) Effects of the composition of AFG and FruArg on the genes related to penis senescence in senescence

[0096] Table 4 Relative expression values of genes related to senescence in rats in each test group

[0097] P53 P21 C 1.00±0.06a 1.00±0.05a D 14.55±1.98c 10.3±1.92c P 2.12±0.47a 1.26±0.22a Sample-1 2.37±0.42a 1.91±0.41a Sample-2 2.45±0.47a 2.11±0.49a Sample-3 2.13±0.41a 2.03±0.37a Sample-4 4.75±0.55b 3.76±0.59b Sample-5 5.32±0.83b 4.49±0.77b

[0098] Note: a - c indicate that groups marked with different letters for the same index have significant differences (P < 0.05).

[0099] As shown in Table 4, compared with the D-gal model group, the expressions of the related marker genes p53 and p21 in the penis of rats in the AFG and FruArg composition group caused by aging were significantly decreased (P<0.01). Among them, the regulation effects of Sample-1, 2, and 3 groups were comparable to those of the positive control group (P>0.05), and were significantly better than those of Sample-4 and 5 groups (P<0.05), indicating that the AFG and FruArg composition can improve the aging state of penile tissues in the aging body, and its effect is better when the mass ratio of AFG and FruArg is between 5:1 and 1:3.

[0100] 3) Effects of the composition of AFG and FruArg on erectile dysfunction caused by aging

[0101] Table 5 Number of penile erections of rats in each experimental group within a specified time

[0102] Average number of erections C 6.17±1.17c D 1.17±0.75a P 5.00±0.63c Sample-1 5.8±0.72c Sample-2 5.6±0.77c Sample-3 5.85±0.78c Sample-4 3.4±0.47b Sample-5 2.7±0.42b

[0103] Note: a~c indicate that groups marked with different letters have significant differences (p<0.05).

[0104] As shown in Table 5, compared with the D-gal model group, the number of penile erections of rats in the AFG and FruArg composition treatment group was significantly increased (P<0.01). There was no significant difference between Sample-1, 2, and 3 groups and the positive control group (P>0.05), and they were significantly better than Sample-4 and 5 (P<0.05).

[0105] In summary, the composition of AFG and FruArg can effectively relieve sexual dysfunction caused by aging, improve the aging state of penile tissues in the aging body and increase the average number of erections. Among them, the effect is optimal when the mass ratio of AFG and FruArg is between 5:1 and 1:3.

[0106] Example 2

[0107] A preparation method of a red ginseng product capable of relieving male sexual dysfunction caused by aging is carried out according to the following steps:

[0108] (1) Select fresh and insect-free ginseng, adjust its moisture content to 65% and then seal it; the specific operation of moisture adjustment is: place the ginseng in an oven at 55°C to remove moisture to 65%; the moisture content is detected using a rapid moisture content detector.

[0109] (2) Keep the sealed ginseng at 55°C for 48 hours, and then measure the glucose, maltose, and arginine contents in the ginseng; after detection, the glucose content in the ginseng changed from 1.30% to 2.84% before and after incubation, the maltose content increased from 2.2% to 10.56%, and the arginine content changed from 3.88% to 4.15%.

[0110] (3) Open the package, place the ginseng after heat preservation in an oven at 95 °C to remove moisture until its moisture content is reduced to 30%;

[0111] (4) Seal the ginseng processed in step (3) again and keep it at 95 °C for heat preservation for 150 minutes;

[0112] (5) Open the package, place the ginseng processed in step (4) under the condition of 105 °C and dry it until the moisture content is lower than 10%;

[0113] (6) Crush, weigh and package the ginseng obtained after the treatment in step (5) to obtain the red ginseng product.

[0114] After detection, the sum of the contents of AFG and FruArg in the red ginseng product is 78.86 mg / g DW, among which the content of AFG is 60.69 mg / g DW, the mass of FruArg is 18.17 mg / g DW, the ratio of AFG:FruArg is 3.34:1, the content of 5-HMF is 0.0586 mg / g DW, and the content of AA is 0.0314 mg / g DW.

[0115] Example 3

[0116] A preparation method of a processed polygonatum product that can relieve male sexual dysfunction caused by aging is carried out according to the following steps:

[0117] (1) Select fresh and insect-free polygonatum respectively, adjust its moisture content to 70% and then seal it; the specific operation of moisture adjustment is: place the polygonatum in an oven at 55 °C to remove moisture to 70%; the moisture content is detected by using a rapid moisture content detector;

[0118] (2) Keep the sealed polygonatum at 55 °C for 60 hours, and measure the contents of glucose, maltose and arginine in the polygonatum; after detection, the glucose content in the polygonatum before and after heat preservation changes from 2.50% to 2.77%, the maltose content increases from 2.30% to 3.17%, and the content of arginine changes from 1.65% to 1.89%;

[0119] (3) Open the package, place the polygonatum after heat preservation in an oven at 95 °C to remove moisture until its moisture content is reduced to 20%;

[0120] (4) Seal the polygonatum processed in step (3) again and keep it at 100 °C for heat preservation for 30 minutes;

[0121] (5) Open the package, place the polygonatum processed in step (4) in an oven at 100 °C and dry it until the moisture content is lower than 10%;

[0122] (6) Weigh and package the polygonatum sibiricum processed in step (5) to obtain the processed polygonatum sibiricum product.

[0123] After testing, the sum of the contents of AFG and FruArg in the processed polygonatum sibiricum product is 28.35 mg / g DW, among which the AFG content is 16.07 mg / g DW, the FruArg content is 12.28 mg / g DW, the ratio of AFG:FruArg is 1.3:1, the 5-HMF content is 0.061 mg / g DW, and the acrylamide content is 0.0349 mg / g DW.

[0124] Example 4

[0125] A preparation method of a processed cistanche deserticola product capable of alleviating male sexual dysfunction caused by aging is carried out according to the following steps:

[0126] (1) Select fresh and non-insect-eaten cistanche deserticola, adjust its moisture content to 80% and then seal it; the specific operation of moisture adjustment is: place the cistanche deserticola in an oven at 50 °C to remove moisture until it reaches 80%; the moisture content is detected using a rapid moisture content detector.

[0127] (2) Keep the sealed cistanche deserticola at 50 °C for 72 hours, and measure the glucose, maltose, and arginine contents in the cistanche deserticola; after testing, the glucose content in the cistanche deserticola changes from 3.16% to 4.84% before and after heat preservation, the maltose content increases from 1.02% to 2.06%, and the arginine content changes from 1.34% to 1.51%.

[0128] (3) Open the package, and place the heat-preserved cistanche deserticola in an oven at 95 °C to remove moisture until its moisture content is reduced to 15%.

[0129] (4) Seal the cistanche deserticola processed in step (3) again and keep it at 105 °C for 30 minutes.

[0130] (5) Open the package, and place the cistanche deserticola processed in step (4) at 105 °C to dry until the moisture content is lower than 10%.

[0131] (6) Crush, weigh, and package the cistanche deserticola processed in step (5) to obtain the processed cistanche deserticola product.

[0132] After testing, the sum of the contents of AFG and FruArg in the processed cistanche deserticola product is 25.77 mg / g DW, among which the AFG content is 7.39 mg / g DW, the mass of FruArg is 18.38 mg / g DW, the ratio of AFG:FruArg is 0.4:1, the 5-HMF content is 0.0186 mg / g DW, and the AA content is 0.0155 mg / g DW.

[0133] Example 5

[0134] A preparation method of red ginseng-polygonatum sibiricum processed product capable of alleviating male sexual dysfunction caused by aging is carried out according to the following steps:

[0135] (1) Select fresh and insect-free ginseng and polygonatum sibiricum respectively, adjust their moisture content to 65% and then seal; the specific operation of moisture adjustment is: place ginseng and polygonatum sibiricum in an oven at 60 °C to remove moisture to 65%; the moisture content is detected using a rapid moisture content detector;

[0136] (2) Keep the sealed ginseng and polygonatum sibiricum at 60 °C for 72 hours respectively, and measure the contents of glucose, maltose and arginine in ginseng and polygonatum sibiricum; after detection, the glucose content in ginseng before and after heat preservation changes from 1.24% to 2.76%, the maltose content increases from 2.56% to 10.08%, and the content of arginine changes from 3.84% to 4.29%; the glucose content in polygonatum sibiricum before and after heat preservation changes from 2.50% to 2.85%, the maltose content increases from 2.30% to 3.32%, and the content of arginine changes from 1.65% to 1.94%;

[0137] (3) Open the package, place the heat-preserved ginseng and polygonatum sibiricum in an oven at 95 °C to remove moisture until their moisture content is reduced to 25%;

[0138] (4) Mix the ginseng and polygonatum sibiricum processed in step (3) according to a mass ratio of 1:1, pulverize them, seal them again and keep them at 105 °C for 60 minutes;

[0139] (5) Open the package, place the combined material processed in step (4) in an oven at 105 °C to dry until the moisture content is lower than 10%;

[0140] (6) Weigh and package the material obtained in (5) to obtain the red ginseng-polygonatum sibiricum processed product.

[0141] After detection, the sum of the contents of AFG and FruArg in the red ginseng-polygonatum sibiricum processed product is 55.42 mg / g DW, the AFG content is 40.46 mg / g DW, the mass of FruArg is 14.96 mg / g DW, the ratio of AFG:FruArg is 2.7:1, the 5-HMF content is 0.0565 mg / g DW, and the AA content is 0.0177 mg / g DW.

[0142] Example 6

[0143] A preparation method of red ginseng-cistanche deserticola processed product capable of alleviating male sexual dysfunction caused by aging is carried out according to the following steps:

[0144] (1) Select fresh and insect-free ginseng and cistanche, combine them according to a mass ratio of 2:1, pulverize to obtain a composite raw material, adjust its moisture content to 70% and then seal it; the specific operation for moisture adjustment is: place the ginseng and cistanche in an oven at 55°C to remove moisture until it reaches 70%; the moisture content is detected using a rapid moisture content detector;

[0145] (2) Keep the sealed composite raw material at 55°C for 60 hours, and measure the contents of glucose, maltose, and arginine in the composite raw material. After testing, before and after the heat preservation, the glucose content in this ginseng and cistanche combination changed from 2.24% to 3.76% (dry weight), the maltose content increased from 2.24% to 6.78% (dry weight), and the arginine content changed from 2.25% to 2.95% (dry weight);

[0146] (3) Open the package, place the heat-preserved composite raw material in an oven at 95°C to remove moisture until its moisture content is reduced to 20%;

[0147] (4) Seal the composite raw material treated in step (3) again and keep it at 100°C for 30 minutes;

[0148] (5) Open the package, place the composite raw material treated in step (4) in an oven at 100°C to dry until the moisture content is less than 10%;

[0149] (6) Weigh and package the composite raw material obtained from step (4) to obtain the processed product of red ginseng - cistanche.

[0150] After testing, the sum of the contents of AFG and FruArg in the processed product of red ginseng - cistanche is 44.22 mg / g DW, among which the AFG content is 29.12 mg / g DW, the mass of FruArg is 15.10 mg / g DW, the ratio of AFG:FruArg is 1.92:1, the 5-HMF content is 0.035 mg / g DW, and the AA content is 0.031 mg / g DW.

[0151] Example 7

[0152] A preparation method of a ginseng - polygonatum - cistanche composite processed product capable of alleviating male sexual dysfunction caused by aging is carried out according to the following steps:

[0153] (1) Select fresh and insect-free ginseng, polygonatum, and cistanche, combine them according to a mass ratio of 1:1:1, pulverize to obtain a composite raw material, adjust its moisture content to 70% and then seal it; the specific operation for moisture adjustment is: place the ginseng, polygonatum, and cistanche in an oven at 50°C to remove moisture until it reaches 70%; the moisture content is detected using a rapid moisture content detector;

[0154] (2) Keep the sealed composite raw material at 50 °C for 72 hours, and measure the contents of glucose, maltose, and arginine in the composite raw material; after testing, before and after the heat preservation, the glucose content in the ginseng-polygonatum cyrtonema-herba cistanches combination material changed from 3.54% to 5.66%, the maltose content increased from 3.08% to 5.45%, and the arginine content changed from 2.25% to 2.95%;

[0155] (3) Open the package, place the composite raw material processed in step (2) in a non-closed environment, evaporate the water content at 90 °C until it is as low as 20%, and then steam it in a closed state at 90 °C for 120 minutes;

[0156] (4) Take out the composite raw material obtained in step (3) and dry it at 90 °C until the water content is lower than 10%;

[0157] (5) Weigh and vacuum-seal the composite raw material obtained in step (4), and obtain the processed product of ginseng-polygonatum cyrtonema-herba cistanches after packaging.

[0158] After testing, the sum of the contents of AFG and FruArg in the processed product of ginseng-polygonatum cyrtonema-herba cistanches is 32.07 mg / g DW, among which the AFG content is 15.82 mg / g DW, the mass of FruArg is 16.25 mg / g DW, the ratio of AFG:FruArg is 0.97:1, the 5-HMF content is 0.0198 mg / g DW, and the AA content is 0.0152 mg / g DW.

[0159] Example 8

[0160] A preparation method of a processed product of polygonatum cyrtonema-herba cistanches capable of alleviating male sexual dysfunction caused by aging is carried out according to the following steps:

[0161] (1) Select fresh and non-insect-eaten polygonatum cyrtonema and herba cistanches, combine them according to a mass ratio of 1:2 and then crush to obtain a composite raw material, adjust its water content to 80% and then seal it; the specific operation of water content adjustment is: place polygonatum cyrtonema and herba cistanches in an oven at 50 °C to remove water until it reaches 80%; the water content is detected using a rapid water content detector;

[0162] (2) Keep the sealed composite raw material at 50 °C for 72 h, and measure the contents of glucose, maltose, and arginine in the composite raw material; after testing, before and after the heat preservation, the glucose content in the polygonatum cyrtonema-herba cistanches combination material changed from 3.28% to 4.88%, the maltose content increased from 1.09% to 2.49%, and the arginine content changed from 2.06% to 2.35%;

[0163] (3) Open the package, place the heat-preserved composite raw material in an oven at 105 °C to remove water until its water content is reduced to 20%;

[0164] (4) Seal the composite raw material processed in step (3) again and keep it at 105 °C for 60 minutes;

[0165] (5) Open the package and dry the composite raw material processed in step (4) in an oven at 105 °C until the moisture content is lower than 10%;

[0166] (6) Weigh and package the composite raw material obtained after the treatment in step (5) to obtain the processed product of Polygonatum sibiricum - Cistanche deserticola.

[0167] After detection, the sum of the contents of AFG and FruArg in the processed product of Polygonatum sibiricum - Cistanche deserticola is 26.37 mg / g DW, among which the content of AFG is 6.60 mg / g DW, the mass of FruArg is 19.77 mg / g DW, the ratio of AFG:FruArg is 0.33:1, the content of 5 - HMF is 0.0358 mg / g DW, and the content of AA is 0.0212 mg / g DW.

[0168] Comparative Example 1

[0169] A preparation method of red ginseng product is carried out according to the following steps:

[0170] (1) Select fresh and insect - free ginseng, adjust its moisture content to 65% and then seal it; the specific operation of moisture adjustment is: place the ginseng in an oven at 55 °C to remove moisture until it reaches 65%; the moisture content is detected using a rapid moisture content detector;

[0171] (2) Keep the sealed ginseng at 55 °C for 48 hours, and then measure the contents of glucose, maltose, and arginine in the ginseng; after detection, the glucose content in the ginseng before and after insulation changes from 1.30% to 2.84%, the maltose content increases from 2.2% to 10.56%, and the arginine content changes from 3.88% to 4.15%;

[0172] (3) Seal the ginseng processed in step (2) and keep it at 95 °C for 150 minutes;

[0173] (4) Open the package and dry the ginseng processed in step (3) under the condition of 105 °C until the moisture content is lower than 10%;

[0174] (5) Crush, weigh, and package the ginseng obtained after the treatment in step (4) to obtain the red ginseng product.

[0175] After detection, the sum of the contents of AFG and FruArg in the red ginseng product is 41.25 mg / g DW, among which the AFG content is 36.09 mg / g DW, the mass of FruArg is 5.16 mg / g DW, the ratio of AFG:FruArg is 6.99:1, the 5-HMF content is 0.0306 mg / g DW, and the AA content is 0.0183 mg / g DW.

[0176] Comparative Example 2

[0177] A preparation method of a red ginseng product is carried out according to the steps in Example 2, wherein only the reduced moisture content in step (3) is adjusted to 50%, and the red ginseng product is obtained.

[0178] After detection, the sum of the contents of AFG and FruArg in the red ginseng product is 57.23 mg / g DW, among which the AFG content is 49.15 mg / g DW, the mass of FruArg is 8.08 mg / g DW, the ratio of AFG:FruArg is 6.08:1, the 5-HMF content is 0.0429 mg / g DW, and the AA content is 0.0215 mg / g DW.

[0179] Comparative Example 3

[0180] A preparation method of a red ginseng product is carried out according to the steps in Example 2, wherein only the reduced moisture content in step (3) is adjusted to 10%, and the red ginseng product is obtained.

[0181] After detection, the sum of the contents of AFG and FruArg in the red ginseng product is 30.78 mg / g DW, among which the AFG content is 27.51 mg / g DW, the mass of FruArg is 3.27 mg / g DW, the ratio of AFG:FruArg is 8.41:1, the 5-HMF content is 0.0136 mg / g DW, and the AA content is 0.0079 mg / g DW.

[0182] Comparative Example 4

[0183] A preparation method of a red ginseng product is carried out according to the steps in Example 2, wherein only the moisture content in step (1) is adjusted to 90%, and the red ginseng product is obtained.

[0184] After detection, the sum of the contents of AFG and FruArg in the red ginseng product is 69.31 mg / g DW, among which the AFG content is 58.57 mg / g DW, the mass of FruArg is 10.74 mg / g DW, the ratio of AFG:FruArg is 5.45:1, the 5-HMF content is 0.0482 mg / g DW, and the AA content is 0.0253 mg / g DW.

[0185] Comparative Example 5

[0186] A preparation method of red ginseng products was carried out according to the steps in Example 2, wherein only the moisture content in step (1) was adjusted to 50%, and red ginseng products were prepared.

[0187] After detection, the sum of the contents of AFG and FruArg in the red ginseng products was 61.81 mg / g DW, wherein the content of AFG was 52.89 mg / g DW, the mass of FruArg was 8.92 mg / g DW, the ratio of AFG:FruArg was 5.93:1, the content of 5-HMF was 0.0385 mg / g DW, and the content of AA was 0.0183 mg / g DW.

[0188] By comparing Comparative Example 1 and Example 2, it can be seen that the sum of the contents of AFG and FruArg in the red ginseng products prepared by the process lacking step (3) decreased, and at the same time, the ratio of AFG:FruArg did not meet the requirements for effectively alleviating male sexual dysfunction caused by aging. In addition, if the moisture content in step (3) was adjusted too high (Comparative Example 2) or too low (Comparative Example 3), it would also lead to a decrease in the contents of AFG and FruArg, and the ratio of AFG:FruArg did not meet the requirements for effectively alleviating male sexual dysfunction caused by aging.

[0189] By comparing Comparative Examples 4, 5 and Example 2, it can be found that the moisture control in step (1) is also related to the sum of the contents of AFG and FruArg in the obtained red ginseng products and its effect on alleviating male sexual dysfunction. Too high (Comparative Example 4) or too low (Comparative Example 5) moisture content will also cause the contents of AFG and FruArg to decrease and affect the ratio of AFG:FruArg.

[0190] In summary, the moisture control in steps (1) and (3) is crucial for increasing the sum of the contents of AFG and FruArg in the processed products and meeting the requirement that the ratio of AFG:FruArg is between 5:1 and 1:3. The moisture content in step (1) should be controlled at 65% - 80%, and the moisture content in step (3) should be controlled at 15% - 30%.

[0191] Evaluation of the effect of food ingredients rich in AFG and FruArg in Example 9 on improving senile erectile dysfunction

[0192] Experimental animals: 40 healthy male 8-week-old SPF-grade SD rats.

[0193] Experimental grouping: Group C: blank control group; gavaged with 0.5% CMC-Na normal saline; Group D: D-galactose (D-gal) model control group; gavaged with 0.5% CMC-Na normal saline; Group P: tadalafil positive control group, gavaged with 0.52 mg / kg BW; Sample-L group: low-dose sample group, AFG:FruArg = 5:1, gavaged with the sample at a total of 40 mg / kg BW calculated as the sum of AFG and FruArg; Sample-H group: high-dose sample group, AFG:FruArg = 1:3, gavaged with the sample at a total of 80 mg / kg BW calculated as the sum of AFG and FruArg.

[0194] Except for Group C, the other groups were intraperitoneally injected with D-gal at a dose of 150 mg / kg BW every day for 9 consecutive weeks. Starting from the 6th week, intraperitoneal injection and gavage were carried out simultaneously for 4 consecutive weeks.

[0195] The sample used in the Sample-L group was from the red ginseng product prepared in Example 2; the sample used in Sample-H was from the polygonatum cistanche product prepared in Example 8.

[0196] Test results:

[0197] 1) Effects of AFG and FruArg on aging body weight and penis weight

[0198] Table 6 Average body weight and penis mass of rats in each group during the test

[0199] C D P Sample-L Sample-H Average body weight change (g) 230.14±10.92a 226.57±9.98a 232.86±10.49a 233.71±12.23a 226.43±8.97a Penis mass (g) 0.77±0.07a 0.77±0.05a 0.79±0.06a 0.80±0.08a 0.78±0.04a

[0200] Note: a indicates that for the same index, there is no significant difference between different groups (P>0.05).

[0201] As shown in Table 6, there were no significant differences in body weight and penis weight among the groups (P>0.05), indicating that the red ginseng product and the polygonatum cistanche product had no significant regulatory effect on the body weight and penis weight of rats.

[0202] 2) Effects of AFG and FruArg on aging-related marker genes in the aging penis

[0203] Table 7 Relative expression values of aging-related marker genes in rats in each test group

[0204] C D P Sample-L Sample-H P53 1.00±0.06a 14.55±1.98d 2.12±0.47c 2.29±0.43c 1.52±0.34b P21 1.00±0.05a 10.3±1.92d 1.26±0.22c 1.94±0.40c 1.44±0.42b

[0205] Note: a-d indicate that groups with different letters for the same index have significant differences (P<0.05).

[0206] As shown in Table 7, compared with the D-galactose (D-gal) model control group, the expressions of two senescence-related genes, p53 and p21, in the penile tissues of rats in the Sample-L group and the Sample-H group were significantly decreased (P<0.01). Among them, the effect of regulating p53 expression in the Sample-H group was better than that in the positive control group (P<0.05), and there was no significant difference in the effect of inhibiting p53 expression between the Sample-L group and the positive control group (P>0.05); there was no significant difference in the effect of inhibiting p21 expression between the Sample-H group and the positive control group (P>0.05). This proves that red ginseng products and polygonatum-cistanche products rich in AFG and FruArg can improve the senescent state of penile tissues in senescent organisms.

[0207] 3) Effects of AFG and FruArg on erectile dysfunction caused by aging

[0208] Table 8 Number of penile erections of rats in each experimental group within a specified time

[0209] Analyte C D P Sample-L Sample-H Average number of erections 6.17±1.17a 1.17±0.75c 5.00±0.63b 5.67±0.81a 5.83±0.75a

[0210] Note: a~c indicate that groups marked with different letters are significantly different (p<0.05).

[0211] As shown in Table 8, compared with the model control group, the number of erections of rats in the Sample-L treatment group and the Sample-H treatment group increased significantly (P<0.01), and the effects of the two experimental groups were better than those of the positive control (P<0.05).

[0212] In summary, the red ginseng products and polygonatum-cistanche products prepared by the present invention are both rich in AFG and FruArg, and the mass ratio of AFG and FruArg is between 5:1 and 1:3, which can effectively alleviate male sexual dysfunction caused by aging.

[0213] The embodiments provided above are not intended to limit the scope covered by the present invention, nor are the described steps intended to limit their execution order. Obvious improvements made by those skilled in the art to the present invention in combination with the existing common general knowledge also fall within the protection scope defined by the claims of the present invention.

Claims

1. A method for preparing a processed product with high AFG and FruArg content and the function of alleviating male sexual dysfunction caused by aging, characterized in that: The preparation method comprises the following steps: (1) taking the processed product raw materials, adjusting the moisture content thereof to 60% to 80%, and then sealing; the processed product raw materials are one or more of ginseng, cistanche deserticola, and polygonatum; (2) keeping the sealed processed product raw materials warm; (3) taking out the processed product raw material after the heat preservation and drying it until the moisture content is reduced to 15-40%; (4) sealing and keeping warm the processed raw material processed in step (3); (5) Taking out the processed product raw material treated in step (4) and drying it until its moisture content is less than 10%, thereby obtaining the processed product.

2. The preparation method according to claim 1, characterized in that: The raw materials for the processed product in step (1) include whole raw materials, cut raw materials, crushed raw materials or pulped raw materials.

3. The preparation method according to claim 1, characterized in that: When the processed raw materials are a mixture of ginseng and polygonatum, the mass ratio of ginseng to polygonatum is 0.5-1.5:1; when the processed raw materials are a mixture of ginseng and Cistanche deserticola, the mass ratio of ginseng to Cistanche deserticola is 1.5-2.5:1; when the processed raw materials are a mixture of polygonatum and Cistanche deserticola, the mass ratio of polygonatum to Cistanche deserticola is 0.5-1.5:2; when the processed raw materials are a mixture of ginseng, polygonatum and Cistanche deserticola, the mass ratio of ginseng, polygonatum and Cistanche deserticola is 0.5-1.5:0.5-1.5:

1.

4. The preparation method according to claim 1, characterized in that: The process of adjusting the moisture content in step (1) is as follows: placing the processed product raw materials at 50-60° C. to remove moisture.

5. The preparation method according to claim 1, characterized in that: The sealing and heat preservation in step (2) is to keep the temperature at 50-60° C. for 48-72 hours.

6. The preparation method according to claim 1, characterized in that: The drying in step (3) includes high temperature drying, natural air drying or reduced pressure drying; the moisture content in step (3) is reduced to 15-30%.

7. The preparation method according to claim 1, characterized in that: The raw material of the processed product processed in step (4) after step (3) is any one of ginseng, Cistanche deserticola and Polygonatum sibiricum processed in steps (1) to (3), or any two or three of ginseng, Cistanche deserticola and Polygonatum sibiricum processed separately in steps (1) to (3), or any two or three of ginseng, Cistanche deserticola and Polygonatum sibiricum processed together in steps (1) to (3).

8. The preparation method according to claim 1, characterized in that: The sealing and heat preservation in step (4) is carried out at a temperature of 90° C. to 110° C. for 30 to 150 minutes.

9. The preparation method according to claim 1, characterized in that: The drying in step (5) includes high temperature drying, natural air drying or reduced pressure drying; the moisture content after drying in step (5) is 8-10%.

10. A processed product with high AFG and FruArg content and the function of alleviating male sexual dysfunction caused by aging, obtained by the preparation method according to any one of claims 1 to 9.

Images